Immunoprophylaxis against Klebsiella and Pseudomonas aeruginosa infections

Journal of Infectious Diseases

Volumn 174, Issue 3, 1996, Pages 537-543

  Donta, Sam T ^a   Peduzzi, Peter ^b   Cross, Alan S ^b   Sadoff, Jerald ^b   Haakenson, Clair ^b   Cryz Jr , Stanley J ^b   Kauffman, Carol ^b   Bradley, Suzanne ^b   Gafford, Glenn ^b   Elliston, Dan ^b   Beam Jr , Thomas R ^b   John Jr , Joseph F ^b   Ribner, Bruce ^b   Cantey, Robert ^b   Welsh, Carolyn H ^b   Ellison III, Richard T ^b   Young, Edward J ^b   Hamill, Richard J ^b   Leaf, Howard ^b   Schein, Roland M H ^b   Mulligan, Maury ^b   Johnson, Caroline ^b   Abrutyn, Elias ^b   McLeod, J Griffiss ^b   Hamadeh, Randa ^b   Eliasson, Arn H ^b   McClain, J Bruce ^b   Melcher, Gregory P ^b   Kelly, J William ^b   Byrne, W Russel ^b   Wallace, Mark ^b   Amundson, Dennis ^b   Gumpert, Barton ^b   Slagle, David ^b   more..

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; IMMUNOGLOBULIN; PSEUDOMONAS VACCINE;

ACTIVE IMMUNIZATION; ARTICLE; BACTEREMIA; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GRAM NEGATIVE INFECTION; HUMAN; HYPERTENSION; IMMUNOPROPHYLAXIS; KLEBSIELLA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

EID: 9544243676     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.3.537     Document Type: Article

References (24)

1. Bryan CS, Reynolds KL, Brenner ER. Analysis of 1186 episodes of gramnegative bacteremia in non-university hospitals: the effects of antimicrobial therapy. Rev Infect Dis 1983;5:629-38.
2. Bodey GP, Bolivar R, Fainstein V, Jadeja L. Infections caused by Pseudomonas aeruginosa. Rev Infect Dis 1983;5:279-313.
3. Thomas FF, Jackson RT, Melly MA, Alford RH. Sequential hospital-wide outbreaks of resistant Serratia and Klebsiella infections. Ann Intern Med 1977;137:581-4.
4. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993;119:353-8.
5. Tomasz A. Multiple-antibiotic-resistant pathogenic bacteria. N Engl J Med 1994;330:1247-50.
6. Cryz SJ Jr, Mortimer P, Cross AS, Furer E, Germanier R. Safety and immunogenicity of a polyvalent Klebsiella capsular polysaccharide vaccine in humans. Vaccine 1986;4:15-20.
7. Cryz SJ Jr, Furer E, Cross AS, Wegmann A, Germanier R, Sadoff JC. Safety and immunogenicity of a Pseudomonas aeniginosa O-polysaccharide toxin A conjugate vaccine in humans. J Clin Invest 1987;80:51-6.
8. Cryz SJ Jr, Furer E, Sadoff JC, Fredeking T, Que JU, Cross AS. Production and characterization of a human hyperimmune intravenous immunoglobulin against Pseudomonas aeruginosa and Klebsiella species. J Infect Dis 1991;163:1055-61.
9. Lan KKG, Wittes J. The B-value: a tool for monitoring data. Biometrics 1988;44:579-85.
10. Pollack M, Young LS. Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man. J Clin Invest 1979;64:276-86.
11. Cross AS, Sadoff JC, Iglewski BH, Sokol PA. Evidence for the role of toxin A in the pathogenesis of infection with Pseudomonas aeniginosa in humans. J Infect Dis 1980;142:538-46.
12. Murray BE. Can antibiotic resistance be controlled? N Engl J Med 1994;330:1229-30.
13. Greene WH, Moody M, Schimpff S, Young VM, Wiernik PH. Pseudomonas aeruginosa resistant to carbenicillin and gentamicin. Ann Intern Med 1973;79:684-9.
14. Maloney J, Rimland D, Stephens DS, Terry P, Whitney AM. Analysis of amikacin-resistant Pseudomonas aeruginosa developing in patients receiving amikacin. Arch Intern Med 1989;149:630-4.
15. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. N Engl J Med 1988;319:902-7.
16. Berkman SA, Lee ML, Gale RP. Clinical uses of intravenous immunoglobulins. Ann Intern Med 1990;112:278-92.
17. National Institutes of Health Consensus Conference. Intravenous immunoglobulin: prevention and treatment of disease. JAMA 1990;264:3189-93.
18. Intravenous Immunoglobulin Collaborative Study Group. Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N Engl J Med 1992;327:234-40.
19. Restino MSR. Formulary update on intravenous immune globulin products. Hosp Pharm Hot Line 1992;1-4.
20. Wolff SN, Fay JW, Herzig RH, et al. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. Ann Intern Med 1993;118:937-42.
21. Groothuis JR, Simoes EAF, Leving MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993;329:1524-30.
22. Dalakas MC, Ilia I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000.
23. Cross AS, Artenstein A, Fredeking T, et al. Safety and immunogenicity of a polyvalent Escherichia coli vaccine in human volunteers. J Infect Dis 1994;170:834-40.
24. Fattom A, Shiloach J, Bryla E, et al. Comparative immunogenicity of conjugates composed of the Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-succinimidyl-3-(2-pyridyldithio)propionate. Infect Immun 1992;60:584-9.